Wolfe Research analyst Alexandria Hammond reiterated an Outperform rating and $1,325.00 price target on Eli Lilly (NYSE: LLY).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

RBC Capital on Eli Lilly (LLY): 'we think the sell-off is overdone'May 4, 2026 10:26 AM Goldman Sachs on Eli Lilly (LLY): 'see the stock weakness as an overreaction'May 4, 2026 9:27 AM Eli Lilly (LLY) PT Raised to $1,400 at Barclays, 'A remarkably strong quarter...and LLY's only just getting started'May 4, 2026 8:58 AM Why Eli Lilly stock is down 3% today: FDA adverse event data explainedMay 4, 2026 8:44 AM Form SCHEDULE 13G ELI LILLY & Co Filed by: VANGUARD CAPITAL MANAGEMENT LLCMay 1, 2026 11:53 AM Eli Lilly (LLY) PT Lowered to $1,133 at BofA SecuritiesMay 1, 2026 10:53 AM Eli Lilly (LLY) PT Raised to $1,344 at Morgan StanleyMay 1, 2026 9:13 AM Novo Nordisk rebrands diabetes tablet as Ozempic in USMay 1, 2026 8:34 AM Eli Lilly (LLY) PT Raised to $1,230 at Cantor FitzgeraldMay 1, 2026 7:13 AM Eli Lilly's oral weight loss drug sees over 5,600 prescriptions in third weekMay 1, 2026 7:03 AM Lilly's Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says BarclaysApril 30, 2026 4:19 PM Form 10-Q ELI LILLY & Co For: Mar 31April 30, 2026 11:26 AM FDA proposes to exclude semaglutide, tirzepatide from compounding listApril 30, 2026 9:23 AM